Marie-France

Tschudin

Mandate and number of AXA shares

Appointed on April 23, 2024 - Term expires at the 2027 Shareholders’ Meeting
First appointment on June 30, 2020
Member of the AXA Compensation, Governance & Sustainability Committee
Number of AXA shares held on March 12, 2024: 3,980

Expertise and experience

Mrs. Marie-France Tschudin graduated with a Master of Business Administration from IMD business school in Switzerland, and a Bachelor of Science from Georgetown University in the United States. Before joining Novartis, Mrs. Marie-France Tschudin spent 10 years at Celgene International in a variety of leadership positions across Europe. She joined Novartis in 2017 as Europe Region Head of Novartis Pharmaceuticals. From March to June 2019, she was President of Advanced Accelerator Applications, a Novartis company. In June 2019, she became President of Novartis Pharmaceuticals. In April 2022, Mrs. Marie-France Tschudin was President, Innovative Medicines International & Chief Commercial Officer of Novartis Pharma AG (Switzerland) and a member of the Executive Committee of Novartis (Switzerland) up until September 2023 when she left the Novartis group.

Mandate held within the AXA Group

• Director: AXA

Mandate held outside the AXA Group

• Director: IMD Foundation (Switzerland)

Mandate held during the last five years

• President, Innovative Medicines International & Chief Commercial Officer: Novartis Pharma AG (Switzerland)
• President: Novartis Pharmaceuticals (Switzerland)
• Director: European Federation of Pharmaceutical Industries and Associations (EFPIA) (Belgium)